Drug Insurance and Psoriasis Severity: A Retrospective Cohort Study
**Background:** Prescription drug insurance in Canada is constituted of a patchwork of public and private insurance plans. The type of drug insurance may have a negative impact on access to treatment for patients covered by public plans compared with private plans. **Objectives:** In patients with p...
Saved in:
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2025-02-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/001c.127820 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | **Background:** Prescription drug insurance in Canada is constituted of a patchwork of public and private insurance plans. The type of drug insurance may have a negative impact on access to treatment for patients covered by public plans compared with private plans.
**Objectives:** In patients with psoriasis treated with advanced therapy in public vs private drug insurance groups, we compared: (1) psoriasis severity scores when an advanced therapy was prescribed, (2) psoriasis severity scores at follow-up, (3) treatment response, and (4) delay between prescription and first dose of advanced therapy.
**Methods:** This unicentric, retrospective cohort study included patients suffering from psoriasis treated by advanced therapy, dermatologist-prescribed between September 2015 and August 2019, in a tertiary academic care center in Québec City, Canada. Data were collected from medical records.
**Results:** Patients treated with an advanced therapy for psoriasis covered under the provincial public drug insurance plan (n = 78) and under a private drug plan (n = 93) did not differ regarding the studied outcomes. Patients’ characteristics differed between groups. Patients in the public group were older (_P_ < .0001), more socioeconomically deprived (_P_ < .05), and more likely to benefit from compassion from the industry to access a prescribed medication free of charge (_P_ < .0001) compared with patients from the privately insured group.
**Discussion:** The high prevalence of compassionate programs from the industry in the public insurance group (42% vs 14%), and the high prevalence of psoriasis on difficult-to-treat areas (face, genitalia, and/or palmoplantar areas) in our cohort (85.4%) may mask differences in access to advanced therapy between the two groups.
**Conclusions:** Prescribers of advanced therapy can be reassured, as we found no inequality in access or care based on patients’ drug insurance coverage. |
---|---|
ISSN: | 2327-2236 |